Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status

Rotunno, Melissa; Sun, Xuezheng; Figueroa, Jonine; Sherman, Mark E; Garcia-Closas, Montserrat; Meltzer, Paul; Williams, Tyisha; Schneider, Sallie Smith; Jerry, D Joseph; Yang, Xiaohong R; Troester, Melissa A

doi:10.1186/bcr3689

Table 5 Forty-one genes associated with parity across all three gene set enrichment analyses ^a

Gene symbol	Gene name	FC^b	P-value^b	FDR^b
CD163L1	Scavenger receptor cysteine-rich type 1 protein M160	1.50	0.00006	0
FCGR2A	Fc fragment of IgG, low affinity IIa, receptor for (CD32)	1.61	0.00006	0
ALOX5AP	Arachidonate 5-lipoxygenase-activating protein	1.52	0.00007	0
VNN1	Vanin 1	1.62	0.00007	0
CD33	CD33 antigen (gp67)	1.54	0.00007	0
CD28	CD28 antigen (Tp44)	1.84	0.00007	0
FCGR2B	Fc fragment of IgG, low-affinity IIb, receptor for (CD32)	1.92	0.00009	0
EAF2	ELL-associated factor 2	1.27	0.00009	0
LCP2	Lymphocyte cytosolic protein 2	1.25	0.00011	0
IL10RA	Interleukin 10 receptor, α	1.32	0.00011	0
BLNK	B-cell linker	1.34	0.00012	0
SAMSN1	SAM domain, SH3 domain and nuclear localization, 1	1.43	0.00013	0
CYB5R4	NADPH cytochrome B5 oxidoreductase	1.33	0.00017	0
HTR2B	5-hydroxytryptamine (serotonin) receptor 2B	1.69	0.00031	0
TTC7A	Tetratricopeptide repeat domain 7A	1.17	0.00032	0
ATP6V1F	ATPase, H + transporting, lysosomal 14 kDa, V1 subunit F	1.20	0.00034	0
TLR7	Toll-like receptor 7	1.28	0.00037	0
ANKRD27	Ankyrin repeat domain 27 (VPS9 domain)	1.19	0.00041	0
ITGAM	Integrin, α M	1.55	0.00044	0
CCDC109B	Hypothetical protein FLJ20647	1.27	0.00045	0
CPVL	Carboxypeptidase, vitellogenic-like	1.48	0.00048	0
LEPROTL1	Leptin receptor overlapping transcript-like 1	1.19	0.00062	0.003
CCR1	Chemokine (C-C motif) receptor 1	1.30	0.00068	0.004
S100A10	S100 calcium binding protein A10	1.45	0.00073	0.004
ALG14	Hypothetical protein MGC19780	1.26	0.00093	0.004
SLC7A7	Solute carrier family 7, member 7	1.30	0.00093	0.004
CHRDL1	Chordin-like 1	1.52	0.00095	0.004
S100A4	S100 calcium binding protein A4	1.40	0.00098	0.004
ITGAE	Integrin α E	1.27	0.00098	0.004
CCL2	Chemokine (C-C motif) ligand 2	1.51	0.00102	0.004
CYP4X1	Cytochrome P450, family 4, subfamily X, polypeptide 1	1.49	0.00128	0.004
CCNDBP1	Cyclin D-type binding-protein 1	1.18	0.00144	0.006
TNFSF13B	Tumor necrosis factor (ligand) superfamily, member 13b	1.30	0.00148	0.006
BLVRA	Biliverdin reductase A	1.24	0.00163	0.006
C8orf40	Hypothetical protein BC013035	1.15	0.00174	0.006
BIN2	Bridging integrator 2	1.20	0.00185	0.006
CD48	CD48 antigen (B-cell membrane protein)	1.26	0.00188	0.006
TSG101	Tumor susceptibility gene 101	1.13	0.00199	0.006
GLRX	Glutaredoxin (thioltransferase)	1.40	0.00200	0.006
B3GALT4	β 1,3-galactosyltransferase, polypeptide 4	1.25	0.00206	0.006

^aFC, Fold change; FDR, False discovery rate; IgG, Immunoglobulin G; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SAM, Sterile α domain. ^bFold change (FC), P-value and false discovery rate (FDR) are derived from gene expression comparison of cancer-free parous versus nulliparous PVLSI women. Genes shown were significantly enriched for PVLSI signature by parity status, that is, in analyses of cancer-adjacent normal tissue overall and estrogen receptor–positive and estrogen receptor–positive tumor tissues.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us